FR0004177046 - Common Stock

**METEX** gets a fundamental rating of **2** out of 10. The analysis compared the fundamentals against 65 industry peers in the **Chemicals** industry. **METEX** may be in some trouble as it scores bad on both profitability and health. **METEX** is valied quite expensively at the moment, while it does show a decent growth rate.

In the past 5 years **METEX** reported 4 times negative operating cash flow.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -19.08% | ||

ROE | -51.84% | ||

ROIC | N/A |

ROA(3y)-0.39%

ROA(5y)-4.87%

ROE(3y)-8.69%

ROE(5y)-13.58%

ROIC(3y)N/A

ROIC(5y)N/A

The **Profit Margin** and **Operating Margin** and **Gross Margin** are not available for **METEX** so they could not be analyzed.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A |

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

The number of shares outstanding for **METEX** remains at a similar level compared to 1 year ago.

Compared to 1 year ago, **METEX** has a worse debt to assets ratio.

Based on the Altman-Z score of **0.19**, we must say that **METEX** is in the distress zone and has some risk of bankruptcy.

With a **Altman-Z score** value of **0.19**, **METEX** is not doing good in the industry: **90.63%** of the companies in the same industry are doing better.

With a **Debt to Equity ratio** value of **0.92**, **METEX** is not doing good in the industry: **79.69%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.92 | ||

Debt/FCF | N/A | ||

Altman-Z | 0.19 |

ROIC/WACCN/A

WACC5.97%

With a decent **Current ratio** value of **2.19**, **METEX** is doing good in the industry, outperforming **64.06%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 2.19 | ||

Quick Ratio | 1.31 |

The earnings per share for **METEX** have decreased strongly by **-137.50%** in the last year.

The Revenue for **METEX** has decreased by **-36.59%** in the past year. This is quite bad

EPS 1Y (TTM)-137.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.65%

Revenue 1Y (TTM)-36.59%

Revenue growth 3Y765.1%

Revenue growth 5Y123.77%

Sales Q2Q%-46.56%

The **Earnings Per Share** is expected to grow by **23.69%** on average over the next years. This is a very strong growth

The **Revenue** is expected to grow by **2.34%** on average over the next years.

EPS Next Y1.9%

EPS Next 2Y23.83%

EPS Next 3Y23.69%

EPS Next 5YN/A

Revenue Next Year-44.08%

Revenue Next 2Y-9.58%

Revenue Next 3Y2.34%

Revenue Next 5YN/A

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

Besides the negative Price/Earnings Ratio, also the **Forward Price/Earnings Ratio** is negative for **METEX**. No positive earnings are expected for the next year.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A |

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | N/A |

A more expensive valuation may be justified as **METEX**'s earnings are expected to grow with **23.69%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.83%

EPS Next 3Y23.69%

No dividends for **METEX**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**METABOLIC EXPLORER**

EPA:METEX (5/6/2024, 7:00:00 PM)

**0.1214**

**+0 (+1.17%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.16M

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | N/A | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -19.08% | ||

ROE | -51.84% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | N/A | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.64

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.92 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 2.19 | ||

Quick Ratio | 1.31 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-137.5%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y1.9%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-36.59%

Revenue growth 3Y765.1%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y